Sebi will act against pharma cos in case of non-disclosure of material information, says Tyagi

Mumbai: Markets regulator Sebi on Thursday said it would take action against pharma companies if they are found not sharing information on material events like inspections and reports by the US FDA.

“It is necessary to share material information even now. If the US FDA (Food and Drug Administration) has taken any action against them (pharmaceutical companies) and they are not disclosing it, if that comes before us, we will take action,” Sebi chairman Ajay Tyagi told reporters here.

He was replying to a specific question pertaining to pharma companies not disclosing actions by drug regulators in foreign markets like the US FDA undertaking inspections of their facilities and passing orders.

There have allegedly been instances of such happenings not being properly disclosed to the investors.

Tyagi said such information that constitutes to be “material information” should be shared with the stock exchanges immediately by the respective companies.

India is one of the world’s biggest pharma exporters and many of the domestic players in the sector are listed on the exchanges.

  • Related Posts

    Three arrested after liquor bottles found at pharma firm

    Patna: Three people were arrested and sent to jail after a large quantity of liquor bottles was found at Cellulas Pharma Private Limited in Kankarbagh during a raid by the…

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    Anton Paar India hosted the first day of NEXUS 2026 at Ramada by Wyndham, Navi Mumbai, bringing together leading experts, scientists, researchers and industry professionals from the pharmaceutical sector for…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Three arrested after liquor bottles found at pharma firm

    Three arrested after liquor bottles found at pharma firm

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    NEXUS 2026 brings pharma experts together to explore next generation analytical technologies

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    National Formulary of India 2026 Lists Unapproved Drugs; DCGI Seeks Urgent Explanation from IPC Over Regulatory Discrepancy

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Six leading mental health organisations unite to launch ‘Humanising Medicine India Initiative’ on World Mental Health Day

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Cancer Drug Prices May Fall By Up To 70% As Government Caps Trade Margins: Sources

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two

    Gujarat FDCA cracks down on four firms for illegal drug sale; cancels licences of two